Triumvira Immunologics: Funding, Investors & Team (Oct 2026)
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
Triumvira Immunologics has raised $55.0M across 1 funding round on record, the most recent an undisclosed round of $55.0M announced in Aug 2020.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Triumvira Immunologics Company Profile and Key Stats
Latest funding round on record: Aug 2020.
Triumvira Immunologics Funding Rounds
Triumvira Immunologics Founders and Leadership Team
No contact details are on record for this team yet.
Triumvira Immunologics Funding Compared to Other Biotechnology Startups
Triumvira Immunologics' latest round of $55.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Triumvira Immunologics in Biotechnology and Austin
Companies Similar to Triumvira Immunologics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Triumvira Immunologics Funding FAQs
What does Triumvira Immunologics do?
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
How much funding has Triumvira Immunologics raised?
Triumvira Immunologics has raised $55.0M across 1 round on record. The most recent is an undisclosed round of $55.0M announced in Aug 2020.
When did Triumvira Immunologics last raise funding?
Triumvira Immunologics' most recent funding round on record is an undisclosed round of $55.0M, announced in Aug 2020.
Who is the CEO of Triumvira Immunologics?
Paul Lammers is listed as CEO at Triumvira Immunologics.
Where is Triumvira Immunologics headquartered?
Triumvira Immunologics is based in Austin, Texas, United States.
How many employees does Triumvira Immunologics have?
Triumvira Immunologics is in the 11-50 employee band.
How does Triumvira Immunologics' funding compare to other Biotechnology startups?
Triumvira Immunologics' latest round of $55.0M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Triumvira Immunologics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Triumvira Immunologics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.